Analysis of KRAS mutation in patients with a single-center non-small cell lung cancer
LI Yuanyuan1 XIANG Tianmin2 CHEN Sixian1 CHEN Yongfeng1 ZHOU Suli1 LU Wei1 ZHANG Zhenzhen2 CAI Yongguang1
1.Division Five, Department of Medical Oncology, Guangdong Nongken Central Hospital, Guangdong Province, Zhanjiang 524002, China;
2.Department of Medical Affairs-Research Collaboration, Singlera Genomics Inc., Shanghai 201318, China
Abstract：Objective To analyze the mutation of KRAS gene in patients with single-center non-small cell lung cancer (NSCLC). Methods Tumor tissue or peripheral blood samples were collected from 210 NSCLC patients diagnosed by pathology in Guangdong Nongken Central Hospital from December 2016 to October 2020. High-throughput sequencing technology was used to detect the mutation rate of KRAS gene exon, the distribution characteristics of mutation sites and the correlation with patient characteristics. Results KRAS mutations rate of 210 NSCLC patients was 13.8% (29 cases). Among these KRAS-mutated cases, codon 12 mutation was observed in 58.6% (17/29), codon G13 mutation in 10.3% (3/29), Q61 mutation in 27.6% (8/29) individuals. Most (24.1%, 7/29) of the cases with Q61 mutations were Q61L. KRAS mutations were associated with the gender (P ＜ 0.05), but had no correlation with smoking history and sample types (P ＞ 0.05). Smoking history was correlated with codons G12/13 mutations (P ＜ 0.05), but had no correlation with Q61L mutation (P ＞ 0.05). KRAS mutations were associated with the gender either in tissue samples or in plasma samples (P ＜ 0.05), but had no correlation with smoking history (P ＞ 0.05). Conclusion The mutation frequency of KRAS in NSCLC patients is similar to the frequency reported in East Asian, but the frequency of KRAS codon Q61L mutation is significantly higher than that reported in the literature, suggesting that KRAS Q61L may be an important driver mutation in NSCLC patients from the single center in the current study.
[1] Siegel RL，Miller KD，Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] Herbst RS，Morgensztern D，Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature，2018，553（7689）：446-454.
[3] Heymach JV，Nilsson M，Blumenschein G，et al. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer [J]. Clin Cancer Res，2006，12（14 Pt 2）：4441s-4445s.
[4] Shaw AT，Kim DW，Nakagawa K，et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer [J]. N Engl J Med，2013，368（25）：2385-2394.
[5] Drilon A，Wang L，Hasanovic A，et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas [J]. Cancer Discov，2013，3（6）：630-635.
[6] Shaw AT，Ou SH，Bang YJ，et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer [J]. N Engl J Med，2014，371（21）：1963-1971.
[7] Solomon BJ，Mok T，Kim DW，et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [J]. N Engl J Med，2014，371（23）：2167-2177.
[8] Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J]. Lancet Oncol，2012，13（3）：239-246.
[9] Román M，Baraibar I，López I，et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target [J]. Mol Cancer，2018，17（1）：33.
[10] Khambata-Ford S，Harbison CT，Hart LL，et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase Ⅲ study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer [J]. J Clin Oncol，2010，28（6）：918-927.
[11] Shaukat I，Kern JJ，H?觟ti N，et al. Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics [J]. Hum Pathol，2019，84：18-25.
[12] Liu L，Liu J，Shao D，et al. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients [J]. Cancer Sci，2017，108（12）：2487-2494.
[13] Lei L，Wang WX，Yu ZY，et al. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations [J]. Transl Oncol，2020，13（2）：329-335.
[14] Chun YJ，Choi JW，Hong MH，et al. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing [J]. PLoS One，2019，14（11）：e0224379.
[15] Yang H，Liang SQ，Schmid RA，et al. New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness [J]. Front Oncol，2019，9：953.
[16] T?觟rm?覿nen VT，Pfeifer GP. Mapping of UV photoproducts within ras proto-oncogenes in UV-irradiated cells: correlation with mutations in human skin cancer [J]. Oncogene，1992，7（9）：1729-1736.
[17] Prior IA，Lewis PD，Mattos C. A comprehensive survey of Ras mutations in cancer [J]. Cancer Res，2012，72（10）：2457-2467.
[18] Colombino M，Paliogiannis P，Cossu A，et al. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma [J]. BMC Pulm Med，2019，19（1）：209.
[19] Ghimessy AK，Gellert A，Schlegl E，et al. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy [J]. Cancers （Basel），2019，11（10）：1514.
[20] Riely GJ，Kris MG，Rosenbaum D，et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma [J]. Clin Cancer Res，2008， 14（18）：5731-5734.
[21] Cheng F，Su L，Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer [J]. Oncotarget，2016，7（30）：48832-48841.
[22] Li RY，Liang ZY. Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response [J]. Chin Med J （Engl），2020，133（20）：2476-2485.
[23] 高宁，杨斌，王慧文，等.非小细胞肺癌患者肿瘤组织和血液样本EGFR基因突变的对比研究[J].中国医师杂志，2019，21（12）：1865-1867.
[24] Li Y，Fu XH，Yuan JQ，et al. Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations [J]. Expert Rev Anticancer Ther，2015，15（6）：715-725.
[25] Calabuig-Fari?觡as S，Jantus-Lewintre E，Herreros-Pomares A，et al. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? [J]. Transl Lung Cancer Res，2016，5（5）：466-482.
[26] Pérez-Callejo D，Romero A，Provencio M，et al. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring [J]. Transl Lung Cancer Res，2016，5（5）：455-465.
京公网安备 11010502046598号